LSP Dementia Fund (Life Sciences Partners)

https://www.lspvc.com

In January 2021 LSP announced the launch of the LSP Dementia Fund, a fund dedicated to fight neurodegenerative diseases. The fund will be managed by Professor Philip Scheltens, a world-renowned dementia scientist and thought leader. The LSP Dementia Fund focuses on all stages of dementia drug and medtech development and as such is the first of its kind in the world. It offers the combination of LSP’s deep investment experience with Philip Scheltens’ impressive scientific acumen and extensive network of dementia experts and research institutions across the globe. The focus will be on finding novel treatments to battle the different neurodegenerative diseases, such as Alzheimer’s disease, that cause dementia, as well as generating a strong financial return for investors. This makes the LSP Dementia Fund a true impact investment. In just a few months, LSP raised €50 million from strategic parties, financial institutions, and family offices. Given this significant appetite of investors, LSP believes the fund will ultimately reach at least €150 million. *

	Start	2021-01-12 closing, first
	Group	EQT (Wallenberg family) (Group)
	Industry	LSP Dementia Fund (Life Sciences Partners)
	Industry 2	antidementic drug
	Person	Kuijten, René R. (Life Sciences Partners 201403 General Partner)
	Person 2	Scheltens, Philip (Life Sciences Partners 202101 Managing Partner + Co-Founder + Professor at Univ Amsterdam)

	Region	Amsterdam
	Country	Netherlands
	City	n. a. Amsterdam
		Address record changed: 2021-01-20

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	50,000,000 (fund size at first closing (2021) 2021-01-12)

		* Document for »About Section«: Life Sciences Partners (LSP). (1/20/21). "Press Release: LSP Leads EUR 21 Million Series B Funding Round in Neurent Medical". Amsterdam.

		Record changed: 2024-02-12